Sepsis and septic shock kill more than 270,000 patients in the United States each year and is the leading cause of death in hospitalized patients. More than 30 clinical trials have failed to improve mortality, highlighting the need for new therapies that address novel mechanisms in sepsis. Within hours of onset of sepsis, the systemic inflammatory response transitions from a hyperinflammatory to a persistent hypoinflammatory or low-grade proinflammatory phase, as well as an immunosuppressive phase, coexistent with multiorgan dysfunctions. Clinical alignment with these states is challenging, emphasizing the unmet need of biochemically relevant biomarkers, their kinetic value, and use of phase-specific therapeutics. This panel will discuss the changing immune response phenotype during sepsis progression and the need to identify phase specific therapeutic targets.
- Provider:Society of Critical Care Medicine
- Activity Link: https://congress2024.sccm.org/aaStatic.asp?SFP=VFJVUUtHWFdAMTU3NjlAQ29uZ3Jlc3MgRGlnaXRhbA
- Start Date: 2024-02-01 06:00:00
- End Date: 2024-02-01 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Critical Care Medicine, Pediatric Critical Care Medicine, Surgical Critical Care